Soleno Therapeutics Secures BTD for DCCR Extended-Release Tablets

Soleno Therapeutics Secures BTD for DCCR Extended-Release Tablets

By, Admin 1 May 2024

Soleno Therapeutics Secures FDA Breakthrough Therapy Designation for DCCR Extended-Release Tablets Targeting Prader-Willi Syndrome (PWS)

Overview

Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO) has announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to diazoxide choline for the treatment of adults and children aged 4 years and older with genetically confirmed Prader-Willi syndrome (PWS) who have hyperphagia. This designation acknowledges the FDA's assessment of preliminary data from the Phase 3 clinical development program, suggesting that diazoxide choline may offer significant improvement over existing therapies on clinically significant endpoints.

 A Significant Milestone

  • Soleno Therapeutics, noted that this designation is a significant milestone for their DCCR clinical development program, emphasizing the seriousness of PWS as a condition and the potential of DCCR to be an effective treatment. 
  • The focus remains on preparing the New Drug Application (NDA) submission for DCCR in PWS, expected in mid-2024.

BTD

The Breakthrough Therapy Designation from the FDA accelerates the development and review of drugs for serious conditions. It involves intensive guidance and organizational commitment, potentially leading to priority review and other actions to expedite the process.

Diazoxide Choline Status

Diazoxide choline has Orphan Drug Designation for PWS in both the U.S. and E.U., as well as Fast Track Designation in the U.S.

Prader-Willi Syndrome

Prader-Willi Syndrome (PWS) affects approximately one in every 15,000 live births, characterized by hyperphagia, a chronic and life-threatening hunger. Current therapies do not effectively address the core symptoms of PWS.

DCCR Tablets

  • DCCR (Diazoxide Choline) Extended-Release Tablets offer a novel once-daily formulation. 
  • Supported by extensive clinical data, including Phase 1 and Phase 2 studies, DCCR has shown promise in addressing hyperphagia and other symptoms associated with PWS. 
  • With multiple regulatory designations, including Orphan Drug, Fast Track, and Breakthrough Therapy, DCCR holds considerable potential as a therapeutic option for PWS patients.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!